Topic: fatty liver disease
The round reunites some of the executives and investors who helped Dezima and Akarna to takeovers by Amgen and Allergan, respectively.
Metacrine is adding to this week's NASH talk after getting off a series B as it aims to combat the fatty liver disorder.
Madrigal Pharmaceuticals has seen some positive snapshot data coming out of its phase 2 fatty liver disease test using an old Roche drug.
In new phase 2 data published today, Gilead says a higher dose of its NASH drug saw statistically significant reductions in liver fat.
CymaBay has taken a look at its ongoing midstage test for its liver med seladelpar, and is happy with what it sees.
UCSD scientists are repurposing the anti-inflammatory drug amlexanox to treat Type 2 diabetes.
J&J has unveiled another clutch of deals and collaborations with industry and academia.
Novartis has bolstered its R&D portfolio for NASH, a progressive fatty liver disease tipped to become a $20 billion to $35 billion market in the coming years, with its second deal in a month.
French biotech Genfit, a leader in the race to sell a new med for fatty liver disease, said in its financials that it will delay its phase 3 NASH trial in patients with liver scarring by four to six months.
Fierce 15 company NGM Bio says it met its primary endpoint of reducing liver fat in NASH patients, with hints of antifibrotic activity, as the small biotech looks to get into the mix with its big biopharma rivals for a blockbuster market.